BCT.V - BriaCell Therapeutics Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.145
+0.005 (+3.57%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.140
Open0.145
Bid0.135 x 0
Ask0.145 x 0
Day's Range0.135 - 0.145
52 Week Range0.095 - 0.195
Volume573,934
Avg. Volume250,284
Market Cap23.04M
Beta4.13
PE Ratio (TTM)N/A
EPS (TTM)-0.039
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 days ago

    Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire

    NEW YORK, Sept. 21, 2018-- via NetworkWire– BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected ...

  • ACCESSWIRE4 days ago

    BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

    Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. NEW YORK, NY / ACCESSWIRE / September 21, 2018 / BriaCell Therapeutics Corp. (BCT.V) (OTCQB: BCTXF) ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today it will present the data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference as well as at The MicroCap Conference, both of which will take place in New York City.

  • GlobeNewswire28 days ago

    Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com

    SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. Dr. Williams, BriaCell’s President & CEO, called in to SmallcapVoice.com to go over the highlights for the Company’s achievements in the summer of 2018 and the expected newsflow from BriaCell in the coming months.

  • GlobeNewswire2 months ago

    BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team

    The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site. BriaCell is currently conducting  an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov as NCT03328026).

  • ACCESSWIRE3 months ago

    BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel

    TORONTO, ON / ACCESSWIRE / June 13, 2018 / BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year's MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell's President and CEO will discuss Bria-IMT™, BriaCell's lead clinical candidate, its potential in treating breast cancer, and its advantages over similar immuno-oncology therapeutics.

  • Breaking Down BriaCell Therapeutics Corp’s (CVE:BCT) Ownership Structure
    Simply Wall St.6 months ago

    Breaking Down BriaCell Therapeutics Corp’s (CVE:BCT) Ownership Structure

    In this article, I’m going to take a look at BriaCell Therapeutics Corp’s (TSXV:BCT) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • BriaCell Therapeutics Corp (CVE:BCT): What Does It Mean For Your Portfolio?
    Simply Wall St.7 months ago

    BriaCell Therapeutics Corp (CVE:BCT): What Does It Mean For Your Portfolio?

    If you are a shareholder in BriaCell Therapeutics Corp’s (TSXV:BCT), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • ACCESSWIRE7 months ago

    Research Reports on, Cronos Group, Antibe Therapeutics, Emerald Health Therapeutics, and BriaCell Therapeutics

    LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Cronos Group, Antibe Therapeutics, ...

  • What’s Ahead For BriaCell Therapeutics Corp (CVE:BCT)?
    Simply Wall St.7 months ago

    What’s Ahead For BriaCell Therapeutics Corp (CVE:BCT)?

    BriaCell Therapeutics Corp (TSXV:BCT), a CA$11.25M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...